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Heparan	   sulfate	   (HS)	   proteoglycan	   chains	   are	   key	   components	   of	   the	   breast	   tumor	  
microenvironment	   that	   critically	   influence	   the	   behavior	   of	   cancer	   cells.	   It	   is	   established	   that	  
abnormal	  synthesis	  and	  processing	  of	  HS	  play	  a	  prominent	  role	  in	  tumorigenesis	  albeit	  mechanisms	  
remain	  mostly	  obscure.	  HS	  function	  is	  mainly	  controlled	  by	  sulfotransferases,	  and	  here	  we	  report	  a	  
novel	   cellular	   and	  pathophysiological	   significance	   for	   the	  3-­‐O-­‐sulfotransferase	  3-­‐OST3A	   (HS3ST3A),	  
catalyzing	  the	  final	  maturation	  step	  of	  HS,	  in	  breast	  cancer.	  We	  show	  that	  3-­‐OST3A	  is	  epigenetically	  
repressed	   in	   all	   breast	   cancer	   cell	   lines	   of	   a	   panel	   representative	   of	   distinct	  molecular	   subgroups,	  
except	   in	   HER2-­‐positive	   (HER2+)	   SKBR3	   cells.	   	   Epigenetic	   mechanisms	   involved	   both	   DNA	  
methylation	   and	   histone	   modifications,	   producing	   different	   repressive	   chromatin	   environments	  
depending	  on	  the	  cell	  molecular	  signature.	  Gain	  and	  loss	  of	  function	  experiments	  by	  cDNA	  and	  siRNA	  
transfection	  revealed	  profound	  effects	  of	  3-­‐OST3A	  expression	  on	  cell	  behavior	   including	  apoptosis,	  
proliferation,	   response	   to	   trastuzumab	   in	   vitro	   and	   tumor	   growth	   in	   xenografted	   mice.	   3-­‐OST3A	  
exerted	  dual	  activities	  acting	  as	  tumor-­‐suppressor	  in	  lumA-­‐MCF-­‐7	  and	  triple	  negative-­‐MDA-­‐MB-­‐231	  
cells,	   or	   as	   an	   oncogenic	   factor	   in	   HER2+-­‐SKBR3	   cells.	   Mechanistically,	   fluorescence-­‐resonance	  
energy	  transfer	   (FRET)-­‐fluorescence-­‐lifetime	   imaging	  microscopy	  (FLIM)	  experiments	   indicated	  that	  
the	   effects	   of	   3-­‐OST3A	   in	   MCF-­‐7	   cells	   were	   mediated	   by	   altered	   interactions	   between	   HS	   and	  
fibroblast	   growth	   factor-­‐7	   (FGF-­‐7).	   Further,	   this	   interplay	   between	   HS	   and	   FGF-­‐7	   modulated	  
downstream	   ERK,	   AKT	   and	   p38	   cascades,	   suggesting	   that	   altering	   3-­‐O-­‐sulfation	   affects	   FGFR2IIIb-­‐
mediated	  signaling.	  Corroborating	  our	  cellular	  data,	  a	  clinical	  study	  conducted	  in	  a	  cohort	  of	  breast	  
cancer	  patients	  uncovered	  that,	   in	  HER2+	  patients,	  high	  level	  expression	  of	  3-­‐OST3A	  in	  tumors	  was	  
associated	  with	   reduced	   relapse-­‐free	   survival.	  Our	   findings	  define	  3-­‐OST3A	  as	  a	  novel	   regulator	  of	  
breast	   cancer	   pathogenicity,	   displaying	   tumor-­‐suppressive	   or	   oncogenic	   activities	   in	   a	   cell-­‐	   and	  
tumor-­‐dependent	  context,	  and	  demonstrate	  the	  clinical	  value	  of	  the	  HS-­‐O-­‐sulfotransferase	  3-­‐OST3A	  
as	  a	  prognostic	  marker	  in	  HER2+	  patients.	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INTRODUCTION	  
 Heparan sulfate proteoglycans (HSPG) are integral components of extracellular matrices 
and cell plasma membranes. They are key determinants of the relationships cells have with 
each other and with their microenvironment, and their role in cancer biology is increasingly 
recognized.1 HS glycosaminoglycan chains of cell surface PG, strategically located at the 
cell-matrix interface, act as co-receptors for numerous signal transduction pathways. HS are 
composed of uronic acid and N-acetylglucosamine repeating disaccharide units covalently 
attached to the core protein of PG through a tetrasaccharide linkage region.2 During 
biosynthesis, HS are subjected to marked structural modifications - mainly epimerization, N-
deacetylation, N- and O-sulfation, catalyzed by numerous enzymes, including HS-O-
sulfotransferases.3,4 The range of biological functions of HS ultimately depends on the fine 
structure of their polysaccharide chain. The 3-O-sulfotransferases (3-OST) form the largest 
multigene family of HS modifying enzymes with seven different isoforms, catalyzing O-
sulfation at position 3 of glucosamine (GlcN) residues to produce at least two functionally 
distinct 3-O-sulfated motifs. Importantly, this relatively rare modification completes the fine-
tuning of HSPG and is responsible for highly specific HS activities.5 The best characterized is 
the anticoagulant property of the 3-O-sulfated anti-thrombin binding motif, primarily 
generated by the 3-OST1 isoform. Although it is mostly documented that 3-OST3A generates 
receptors for Herpes simplex virus type-1 (HSV-1) entry6, other likely biological functions, 
such as regulation of growth factors and their tyrosine kinase receptors signaling remain to be 
explored.  
HSPG are critical effectors of several hallmarks of cancer biology.7 In tumor cells, genes 
involved in the biosynthesis of HSPG are frequently dysregulated. The upregulation of cell-
surface HSPG glypican-1 and syndecan-1 has been described in malignant breast cancer 
tissue8, whilst depletion of the extracellular sulfatase Sulf-1 was reported.9 Disruption of HS 
biosynthetic enzymes results in changes in HS fine structure that critically affect cell-matrix 
interactions, cell signaling and tumor cell behavior, including proliferation, adhesion, 
migration and apoptosis through interplay of complex mechanisms.10 
Recent studies highlight an aberrant modulation of 3-OST gene expression through 
epigenetic mechanisms in various tumors including breast, lung, brain, pancreatic, skin and 
colorectal cancers, suggesting an important role in these pathological conditions.11,12 
However, these reports reveal either anti-oncogenic or tumor-promoting effects, and the 
mechanisms and consequences of 3-OST dysregulation in the cancer process are thus not well 
understood.13,14 We recently showed that epigenetic repression of 3-OST genes in 
chondrosarcoma cells leads to altered HSPG sulfation, and demonstrated tumor-suppressive 
properties of 3-O-sulfation in chondrosarcoma cells.15 
Identification of the molecular mechanisms underlying the role of HS-modifying enzymes 
in breast cancer may open new windows for the design of personalized therapies to overcome 
drug failure and for the discovery of new biomarkers. Here, we demonstrate a critical role of 
3-OST3A in specific breast cancer subtypes. We showed epigenetic repression of 3-OST3A 
in several breast cancer cell lines, and demonstrated its impact on cancer cell behavior by 
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gain and loss of function approaches. Importantly, we examined the influence of 3-OST3A 
expression on clinical outcome in a cohort of breast cancer patients. Our study identifies the 
HS-sulfotransferase 3-OST3A as a novel tumor regulator exerting either tumor-suppressive 
or oncogenic properties in a cell-dependent context, and demonstrates its potential clinical 
value as a prognostic marker in HER2+ breast cancer patients enabling stratification of 
patients for treatment.   
 
	  
RESULTS	  
3-­‐OST3A	  is	  differentially	  repressed	  in	  breast	  cancer	  cell	  lines	  via	  epigenetic	  mechanisms	  
 Prompted by studies from us and others pointing to an epigenetic control of 3-OST 
genes11,15, we determined whether 3-OST3A was regulated epigenetically in breast cancer 
cells. 3-OST3A expression analysis in a panel of cell lines representative of distinct 
molecular subgroups of breast cancer (luminal-A [lumA]: ER+ PR+ HER2-; luminal-B 
[lumB]: ER+ PR+/- HER2+/-; HER2+: ER- PR- HER2+; triple-negative [TN]: ER- PR- 
HER2-16, Table S1) revealed very low mRNA level in BT-474, T-47D and MDA-derived 
cells, and reduced expression in lumA-MCF-7 cells compared to the non-tumorigenic 
epithelial-derived MCF-10A cells (Figure 1A). The highest expression level was for HER2+-
SKBR3 cells.  
 DNA methylation analysis of the 3-OST3A promoter CpG island (Figure S1A) showed 
strong hypermethylation in T-47D and MDA-derived cells, while in MCF-7 cells, 
hypermethylation only occurred downstream from the TSS (Figure 1B). In contrast, 3-OST3A 
was not subject to DNA methylation in SKBR3 and MCF-10A cells (Figure 1B and S1B). 
We established further a link between 3-OST3A hypermethylation and gene expression by 
treating the MCF-7 and MDA-MB-231 cells with 5-aza-2’-deoxycytidine (Aza, 
DNAmethyltransferase (DNMT) inhibitor) and trichostatin A (TSA, histone deacetylase 
(HDAC) inhibitor). In MCF-7 cells, Aza and TSA alone markedly increased 3-OST3A 
mRNA level (Figure 1C), while no additive effect was observed upon combined treatment. 
Conversely in MDA-MB-231 cells, neither Aza nor TSA independently produced a 
significant effect, whereas combined treatment increased expression, suggestive of a co-
operative action between histone deacetylation and DNA methylation (Figure 1C). 
 To provide insight into the differential regulation of 3-OST3A in MCF-7 and MDA-
MB-231 cells, representative of the lumA and TN subtype, respectively, we analyzed several 
epigenetic marks at the 3-OST3A promoter. We first evaluated the abundance of DNMT3A 
and 3B isoforms, and of DNMT1 involved in de novo and maintenance of DNA methylation, 
respectively (Figure 2A). We next examined several Polycomb group (PcG) proteins that 
form large complexes generally associated with CpG island promoters and cause closure of 
local chromatin mainly by affecting histone modifications17. We investigated here enhancer 
of zeste homolog 2 (EZH2) that trimethylates Lys27 of histone 3 (H3K27me3) and is 
associated with the suppressor of zeste 12 (SUZ12) protein to form part of Polycomb 
repressive complex PRC2. To further investigate the crosstalk between DNA methylation and 
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histone modifications, the methyl-CpG-binding protein 2 (MeCP2) that recruits histone 
deacetylases (HDACs) to the methylated regions18 as well as Sin3A that functions as a 
corepressor complex with HDACs and MeCP219 were investigated. In MCF-7 cells, 
enrichment in DNMT3B (Figure 2B) was associated with a strong increase in the repressive 
H3K27me3, but not in the other repressive trimethylated Lys9 of histone 3 (H3K9me3, 
Figure 2C) histone mark. As expected, a decrease in the active mark trimethylated Lys4 of 
histone 3 (H3K4me3) was observed compared to MCF-10A (Figure 2C).  
In MDA-MB-231, a strong increase in abundance of DNMT1 and DNMT3A was associated 
with the presence of repressive H3K9me3 and H3K27me3 and with the depletion of 
H3K4me3 (Figure 2B and 2C). As expected, in MCF-10A cells H3K4me3 was abundant and 
H3K9me3 and H3K27me3 absent (Figure 2C). Interestingly, although 3-OST3A regulation in 
SKBR3 cells does not involve DNA methylation, ChIP analysis suggested that it could 
involve histone modifications (data not shown). The histone H3K27 methyltransferase EZH2 
was abundantly associated with the 3-OST3A gene in MDA-MB-231 whereas it was less 
recruited in MCF-7 cells, while SUZ12 was present at low levels (Figure 2D). These data 
suggest that proteins of the PRC2 complex mediate 3-OST3A gene repression in combination 
with DNMT3B in MCF-7 cells, and with DNMT1 and 3A in MDA-MB-231. Investigation of 
the crosstalk between DNA methylation and histone modifications showed that in MCF-7 
cells the recruitment of HDAC1 did not require MeCP2 (Figure 2E), in agreement with the 
observation that Aza and TSA derepressed the promoter independently. Conversely in MDA-
MB-231 cells, MeCP2, HDAC1 and Sin3A were enriched at the 3-OST3A locus (Figure 2E). 
Such repressive environment might explain why treatment with both deacetylation and 
methylation inhibitors is required to reactivate 3-OST3A expression in the latter cells. The 
distinct repressive complexes in the two cell lines are schematically depicted in Figure 2F.  
	  
3-­‐OST3A	   exerts	   tumor-­‐suppressive	   or	   pro-­‐oncogenic	   effects	   depending	   on	   tumor	   cell	  
phenotype	  and	  influences	  response	  to	  trastuzumab	  	  	  	  
 Having demonstrated different expression level and epigenetic behavior in lumA-MCF-7, 
TN-MDA-MB-231, and HER2+-SKBR3 cells, we next interrogated the functional impact of 
3-OST3A expression in these cell lines by gain and loss of function experiments. 
Overexpression moderately reduced cell growth rate in MCF-7 cells and completely inhibited 
cell proliferation in MDA-MB-231 cells (Figure 3A). Importantly, in SKBR3 cells, 3-OST3A 
expression produced the opposite effect, enhancing proliferation, whereas its knockdown by 
siRNA transfection consistently reduced cell growth (Figure 3A). These data emphasize the 
cell-context dependent outcome of HS 3-O-sulfation upon 3-OST3A overexpression or 
silencing, that we showed by performing immunofluorescence staining experiments using 
specific HS4C3 antibodies20 (data not shown). A cornerstone of HER2 therapeutic strategies 
involves the use of a humanized monoclonal anti-HER2 antibody (trastuzumab) leading us to 
analyze the influence of 3-OST3A expression on HER2+-SKBR3 drug response. 
Significantly, trastuzumab exerted a stronger antiproliferative effect in 3-OST3A-expressing 
than in vector-transfected cells, whereas its influence was abrogated following 3-OST3A 
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siRNA knockdown (Figure 3B), indicating that 3-OST3A not only acts as a tumor regulator 
but also modulates anticancer drug sensitivity. 
 Analysis of apoptosis using Annexin V staining showed that 3-OST3A expression was 
pro-apoptotic in MCF-7 cells (Figure 4A), but not in MDA-MB-231 and SKBR3 cells 
(Figure S2). Further investigation of the cell survival mechanisms in MCF-7 cells showed 
enhanced expression of the pro-apoptotic protein Bax and decreased expression of the anti-
apoptotic Bcl-2 (Figure 4B). 3-OST3A also activated caspase-mediated apoptosis, producing 
an increase in cleaved caspase 9 and in the proteolytic cleavage of poly(ADP-
ribose)polymerase (PARP) (Figure 4B). This was accompanied by DNA fragmentation, as 
shown by a TUNEL assay (Figure 4C). These lines of evidence indicating that 3-OST3A 
expression results in reduced cell growth and promotes cell survival in MCF-7 cells prompted 
us to investigate its effect in xenografted mice. 
 SCID mice were transplanted with genetically engineered MCF-7-3-OST3A cell lines in 
two separate experiments (Figure 4D). A clear trend towards reduced tumor size was 
observed in mice implanted with MCF-7-3-OST3A-A cells compared with empty vector-
transfected cells, reaching significance at 6 and 12 weeks (Figure 4E, and S3A). Moreover, 
MCF-7-3-OST3A-B cells exhibited retarded tumor progression from 8 to 18 weeks following 
implantation (Figure 4F and S3B). Together, these in vivo experiments provide strong 
supporting evidence for the 3-OST3A pro-apoptotic and antiproliferative properties observed 
in vitro, indicating that 3-OST3A acts as a tumor-suppressor in a model of lumA breast 
tumors.	  
	  
3-­‐OST3A	  affects	  FGF-­‐7-­‐HS	  interactions	  and	  regulates	  FGF-­‐7	  signaling	  
 HSPGs influence the tumor process by regulating the activity of a variety of signaling 
molecules, primarily FGFs.21 FGF-7 (keratinocyte growth factor) acting on epithelial cells22 
is a potent mitogen for mammary glands23,24, and induces proliferation and motility in breast 
cancer cells.25 This led us to explore the influence of 3-OST3A expression on FGF-7-HS 
interactions and signaling. FGF-7 binding was analyzed by confocal microscopy, flow 
cytometry and, to directly assess FGF-7 and HS interactions, by FRET-FLIM assays in MCF-
7 cells compared to MCF-10A cells. siRNA transfected MCF-10A cells displayed a strong 
pericellular immunofluorescent staining pattern, consistent with enhanced FGF-7 binding, 
whereas FGF-7 staining was reduced in MCF-7 upon 3-OST3A expression (Figure 5A and 
5B). Quantitative flow cytometry clearly confirmed an increase in fluorescence signal 
associated with FGF-7 binding in siRNA transfected MCF-10A, and a decrease in 3-OST3A 
transfected MCF-7 cells (Figure 5C). 
 In a FRET assay (Figure S4), a clear increase in emission intensity of HS-AlexaFluor 555 
was observed in empty vector transfected MCF-7 cells compared to those transfected with 3-
OST3A (Figure S4A). Lambda scan showed a significant FRET from FGF-7-AlexaFluor 488 
to HS-AlexaFluor 555 in cells that did not express 3-OST3A-HA (Figure S4B). FLIM 
analysis confirmed a greater distribution in favor of the FRET positive cell population (in 
green) in control cells, compared to 3-OST3A transfected cells (Figure 5D). The average 
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lifetime of AlexaFluor 488 was unchanged in cells expressing 3-OST3A-HA, but reduced in 
control and 3-OST3A-HA-negative cells (Figure 5E, Table 1). These data indicate that 
binding of FGF-7 is HS-dependent, and that it is impaired upon 3-OST3A overexpression in 
MCF-7 cells, highlighting the potential impact of 3-O-sulfation on FGF-7-HS interactions.  
 We next examined whether impaired FGF-7-HS interactions mediated by 3-OST3A would 
affect FGF-7 downstream signaling pathways. FGF-7 activates the Ras-MAP kinase and 
PI3K-AKT cascades following binding to its receptor FGFR2IIIb, a splice variant of FGFR2 
expressed in breast carcinoma cell lines.26,27 Indeed, phosphorylation of AKT was reduced 
upon FGF-7 treatment at low dose in 3-OST3A-transfected MCF-7 cells (Figure 5F). 
Furthermore, ERK phosphorylation was strongly inhibited upon 3-OST3A transfection from 
0.5 to 1 ng/mL (Figure 5G), whereas phosphorylation of p38 was increased in response to 
FGF-7 treatment (Figure 5H). In empty vector transfected MCF-7 cells, a slight increase in 
ERK phosphorylation was observed at the highest FGF-7 concentration and exposure time 
(Figure S5A) whereas no variations in AKT and p38 phosphorylation occurred (Figure S5B 
and C). Our results suggest that inactivation of the FGF-7-induced ERK signaling pathway is 
involved in the antiproliferative effect of 3-OST3A in lumA-MCF-7 cells, and that inhibition 
of FGF-7-AKT, together with activation of FGF-7-p38 signaling, contributes to its pro-
apoptotic effect (as represented Figure S6). 
3-­‐OST3A	  is	  a	  prognostic	  marker	  in	  breast	  cancer	  patients	  	  
	   To assess the clinical relevance of our experimental data, we analyzed 3-OST3A 
expression in a cohort of primary breast tumors.28 The cohort was segregated into 4 subtypes 
i.e. lumA, lumB, HER2+ and TN according to the pathological markers recommended by the 
St Gallen breast cancer consensus guidelines16 (Table S2). Consistent with other clinical 
studies, TN and HER2+ breast cancers were the most aggressive breast cancers (Figure S8A). 
All tumors expressed 3-OST3A (Figure 6A) and Kruskal-Wallis analysis indicated that the 
level of 3-OST3A expression was associated with the breast cancer subtype (P<0.017). 
Importantly, 3-OST3A expression was significantly lower in lumA-tumors compared to other 
breast cancer subtypes (Mann-Whitney, P<0.042). This observation suggested that a low 
expression of 3-OST3A contributes to the cancer process in lumA tumors, as corroborated by 
the tumor-suppressive effect mediated by 3-OST3A overexpression in MCF-7 cells (shown 
Figure 3A and 4A). On the other hand, 3-OST3A expression was significantly higher in 
HER2+ tumors (Mann-Whitney, P<0.008), suggesting that in this subtype, elevated 3-
OST3A would favor breast cancer formation and progression, in accordance with its 
oncogenic properties in SKBR3 cells (shown Figure 3A). 
 We next investigated the relationship between 3-OST3A expression and HER2+ patient 
outcome. The optimal cut-off for HER2+ breast tumours was determined by ROC curves29,30 
(Figure S7). Importantly, we showed using univariate analysis that 3-OST3A expression was 
significantly associated with cancer progression (CP) (Fisher exact t test; P≤0.004) and death 
(P≤0.046) in HER2+ breast tumors (Table S3). This was confirmed by Kaplan-Meier log-
rank analyses (CP, χ2 = 7.221, 1 df, P≤0.007; death, χ2 = 3.686, 1 df, P≤0.055, Figure 6B).  
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 In addition to 3-OST3A expression (3ost), tumor size (S) and lymph node metastasis (LN, 
absence or presence) were independently associated with CP in HER2+ breast cancers 
(Figure S8B and C, Table S4-6). We then formed a binary variable (3ost, S, LN) that was 
positive only when the HER2+ patients had a 3-OST3A positive tumor of a diameter larger 
than 20 mm and at least one lymph node metastasis (Figure 6C). Multivariate Cox’s 
regression analysis determined the interdependence degree between these three parameters 
and confirmed that the combined variable (3ost, S, LN) stood out as an independent 
significant predictor of cancer recurrence and death (Table 2). This positive variable (3ost, S, 
LN) enhanced 27-fold the risk of recurrence (Hazard ratio (HR), 27.3; 95% Confidence 
Interval (CI), 3.6 to 207.7). The Omnibus test indicated that the number of HER2+ breast 
tumors is sufficient to support this conclusion (Table 2). The Cox’s Regression analysis was 
further confirmed by Kaplan-Meier log-rank analyses (CP: χ2 = 23.233, 1 df, P<2.10-6, death: 
χ2 = 14.354, 1 df, P<2.10-4, Figure 6C) indicating that the combined variable (3ost, S, LN) 
separated two subtypes of HER2+ breast cancer patients with opposite clinical outcome.  
 The HER2+ breast cancer patients positive for (3ost, S, LN) represented 43% of total 
HER2+ patients and among these patients, 71% (15/21) suffered from recurrence (Figure 6C) 
compared to 44% (16/36) when considering 3-OST3A expression only (Figure 6B), thus 
providing a discriminating biomarker for clinicians. Considering the combined variable 
allowed the identification of 93% (15/16) of patients in whom cancer recurred or who died, 
while the HER2+ patients negative for (3ost, S, LN) had no recurrence over 15 years. Our 
results suggest that the current treatment of HER2+ patients is efficient in 96% (27/28) of the 
(3ost, S, LN) negative patients, while the HER2+ breast cancer patients positive for (3ost, S, 
LN) would benefit from additional or alternative treatment such as trastuzumab. 
	  
DISCUSSION 
 This study reports for the first time the molecular, functional and clinical role of the HS-
sulfotransferase 3-OST3A, a key enzyme controlling the tumor microenvironment, in breast 
cancer. A main result of our work is the unequivocal demonstration that 3-OST3A can 
display either oncogenic or tumor-suppressive effects depending on the cell and tumor 
phenotype. This detailed analysis clarifies conflicting literature that reports contrasting 
effects of 3-OSTs expression on tumorigenesis in different types of cancer and cell 
models.13,14 Importantly, the clinical study performed here shows that 3-OST3A is 
differentially expressed in distinct subtypes of tumors, corroborating our in vitro data, and 
establishes the prognostic value of 3-OST3A as a novel marker in HER2+ breast cancer 
patients.  
 Previous reports including ours have documented the epigenetic repression of several 3-
OST genes in tumor cells.11,15,31 Our study shows that 3-OST3A was repressed and subjected 
to hypermethylation in all breast cancer cell lines tested except in HER2+-SKBR3 cells in 
which, consistently, it was expressed at relatively high level. Further analysis of the 
chromatin interactors at the 3-OST3A promoter showed that the epigenetic regulation not only 
depends upon DNA methylation, but also on repressive histone marks, and involves the 
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recruitment of PcG proteins. We describe here for the first time a fine interplay between 
DNA methylation, histone modifications and epigenetic regulators of the PRC2 complex 
controlling 3-OST3A expression in a cell-context dependent manner. In lumA-MCF-7 cells, 
DNMT3B and the EZH2 subunit of the PRC2 complex involved in writing the repressive 
H3K27me3 mark form a chromatin environment that moderately repressed transcriptional 
activity. In MDA-MB-231 cells, we propose a scenario at the 3-OST3A promoter in which the 
methylated DNA reader MeCP2 is associated with a deacetylase complex formed by Sin3A, 
HDAC1 and possibly H3K9 methyltransferases.18 Altogether the chromatin interactors 
DNMT1, 3A, PcG proteins and the histone marks H3K27me3 and H3K9me3 produce gene 
silencing in these cells. Our demonstration of the HS-sulfotransferase 3-OST3A gene 
methylation and histone modification is in line with previous findings indicating that 
epigenetic dysregulation is an important feature of breast cancer pathobiology and that it 
depends upon the tumor signature.32 Our results validate the potential value of epigenetic 
therapies targeting 3-OST3A together with other silenced critical genes such as those coding 
for the Ras interacting protein RASSF1A33, the estrogen receptor α (ERα)34 and the retinoic 
acid receptor RARα35	   in TN breast cancers. Altogether, our findings support the attractive 
idea that the HS-modifying 3-OST3A sulfotransferase enzyme participates ino the matrix-cell 
dialog through epigenetic mechanisms. 
 FGFs, a significant group of HS ligands, use HSPG as co-receptors to bind specific 
tyrosine kinase receptors promoting signal transduction, and FGF signaling is deregulated in 
many cancer types.36 We thus hypothesized that 3-OST3A epigenetic regulation may alter 
breast cancer cell phenotype through modulation of FGF-dependent intracellular signaling. 
FGF-7 secreted by stromal mesenchymal cells acts on epithelial cells, where it associates 
with the FGFR2IIIb receptor. Alteration of the FGF-7-FGFR2IIIb signaling axis contributes 
to the oncogenic process by activating intracellular kinase cascades including ERK-
dependent proliferation and AKT-mediated cell survival in breast cancer cells37, and anti-
FGFR2IIIb antibodies offer a new therapeutic option.38 Since FGF-7 is one of the most 
structurally specific FGFs with respect to its requirement for a 3-O-sulfated motif to 
coordinate ligand-receptor complex assembly39,40, we investigated whether 3-OST3A 
expression may regulate its signaling pathway to trigger the tumor-suppressive effect 
observed in the lumA-MCF-7 cells. Supporting this assumption, our data show that 
reinstating 3-OST3A expression in these cells: i) impaired interactions between FGF-7 and 
HS chains, ii) inhibited proliferative signals via ERK dephosphorylation, and iii) boosted 
apoptotic signals via AKT dephosphorylation and p38 phosphorylation. Our observations are 
of particular interest since FGF-7 plays a critical role both in mammary gland development 
and breast cancer onset and progression.41 Since 3-O-sulfation is an important modification 
of HS for HS-FGF-7-FGFR2IIIb complex formation42, our data support the idea that this 
modification might contribute to the anti-oncogenic properties of 3-OST3A in lumA cells. 
However, it is of note that the mechanisms underlying impaired FGF-7 binding in MCF-7 
cells upon 3-OST3A expression is not fully understood. We ruled out the possibility that 3-
OST3A would reduce FGFR2IIIb expression (data not shown). On the other hand, according 
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to several reports43, it is hypothesized that 3-O-sulfated HS binding may precede and prevent 
FGF-7 interactions with its FGFR2IIIb receptor. Another possibility is that altered activation 
of fibroblast growth factor receptor substrate 2 (FRS2α) would trigger internalization and 
degradation of FGFR2IIIb thus contributing to attenuate FGF-7 binding and signaling seen in 
our experiments upon 3-OST3A expression. These options are currently under investigation 
in our laboratory. 
Since the effects triggered by 3-OST3A expression in breast cancer cell lines depended on 
their molecular signature, a major aim of the present study was to evaluate the clinico-
pathological impact of 3-OST3A expression in breast cancer. We provided insight into this 
key issue by conducting a clinical study in a cohort of breast cancer patients followed over a 
15-year period. The low expression detected in lumA tumors suggests that 3-OST3A might 
inhibit cancer formation and progression and is consistent with a tumor-suppressive effect in 
this subtype of malignancies. This assumption is supported by our experimental data showing 
a pro-apoptotic and anti-proliferative effect triggered by 3-OST3A expression in MCF-7 
cells, associated with tumor growth retardation in xenografted mice.  
A key finding is that, in HER2+ subtype breast cancer patients, high 3-OST3A expression 
is associated with reduced survival. The SKBR3 cell model harboring this molecular 
signature allowed us to explore the mechanisms underlying our clinical observations. 
Consistently, we showed that 3-OST3A overexpression in SKBR3 cells promotes 
proliferation, whereas its silencing results in the reverse effect. Furthermore, 3-OST3A 
expression enhanced the antiproliferative effect of trastuzumab whereas knocking-down 
expression arrested it. This result has two important outcomes. First, it suggests that 3-
OST3A-mediated HS modification alters the HER2 receptor-mediated signaling pathway, an 
assumption that is currently under investigation. Second, it reveals a novel and potentially 
clinically important effect of 3-OST3A on sensitivity to the therapeutic anti-HER2 antibody 
trastuzumab. Identifying the HER2+ breast cancer patients who might benefit from extended 
adjuvant therapy represents a long-standing conundrum. In our cohort, about 40% of HER2+ 
breast cancer patients given chemotherapy (5-fluorouracil, epirubicin (doxorubicin) and 
campthothecin) suffered from cancer progression, a poor outcome highlighting a currently 
unmet clinical need. This phenomenon, strongly supported by the data presented here, could 
therefore facilitate the stratification of two populations of HER2+ breast cancer patients; one 
3-OST3A positive population with at least one lymph node metastasis and a tumor diameter 
greater than 21 mm who are much more likely (71% chance) to suffer from cancer recurrence 
and death, and thus would clearly benefit from alternative therapy such as trastuzumab, while 
the 3-OST3A negative population has a much better prognosis with lack of recurrence over 
15 years.  
 In conclusion, we show that the sulfotransferase 3-OST3A, involved in the final step of 
HS processing, is a key regulator of tumor cell behavior and anticancer drug response, and 
that its oncogenic or tumor-suppressive effects are cell- and tumor-signature dependent. The 
finding that 3-OST3A expression correlates with cancer progression in HER2+ patients 
highlights its clinical significance for guiding therapeutic options in breast cancer treatment. 
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MATERIALS	  AND	  METHODS	  	  
Cell	  culture,	  drug	  treatment	  and	  transfection	  	  
 Human breast cancer cell lines SKBR3, BT-474, T-47D, MDA-MB-231, MDA-MB-453 
and MDA-MB-468 representative of distinct molecular subgroups (Table S1) and the 
immortalized breast epithelial cell line MCF-10A were from the American Type Culture 
Collection (ATCC). The MCF-7 cell line was from the European Collection of Cell Cultures 
(ECACC). Detailed culture conditions and treatment by Aza and TSA are described in 
Supplementary Materials. Cell lines were transiently or stably transfected with 
pcDNA3.1(+)-3-OST3A-hemagglutinin (HA) or the pcDNA3.1(+) plasmid15,44 and 3-OST3A 
expression was analyzed by immunoblotting using anti-HA antibodies (Table S7). 3-OST3A 
siRNAs (Eurogentec, Table S8) and a negative control (Qiagen) were transfected as in 
Supplementary Materials. siRNA efficacy was verified by RT-qPCR and protein analysis.  
 
RT-­‐qPCR	  analysis	  
 Total RNA was extracted and purified using the RNeasy Mini kit (Qiagen) for cultured 
cells and the QIAzol Lysis reagent (Qiagen) for tumor samples. mRNA level was quantified 
by the 2-ΔΔCt method using primers listed in Table S9. 
 
CpG	   island	   identification,	  methylation	   analysis	   and	   chromatin	   immunoprecipitation	   (ChIP)	  
assay	  
 Genomic DNA was purified using the GenomicPrepDNA isolation kit (GE Healthcare). 
The presence of a canonical CpG island in the proximal promoter region (5’) and first exon 
(3’) of 3-OST3A gene was determined using MethPrimer software. The methylation status of 
two regions was analyzed by bisulfite sequencing15 using sense and antisense primers for 
nested-PCR (Table S10). PCR products subcloned into TOPO-TA® vector (Invitrogen) were 
sequenced in at least three clones. ChIP assay was performed using the Low Cell# ChIP kit 
(Diagenode) using antibodies and PCR primers described in Tables S11 and S12, 
respectively.  
 
Protein	  analysis	  	  
 Immunoblot following SDS-PAGE analysis of cell lysate proteins was performed using 
primary and secondary antibodies listed in Table S7.  
 
FGF-­‐7	  cell-­‐surface	  binding	  assays	  	  
 Cells cultured in Lab-Tek chambers (Thermo-Scientific) or 6-well plates were serum-
starved and incubated with recombinant human FGF-7 (0.5 ng/mL) for 30 min. Cells were 
immunostained for FGF-7 and HS expression using antibodies (Table S7) prior to confocal 
laser scanning microscopy. Alternatively, following immunostaining, cells were fixed in 4% 
(w/v) paraformaldehyde prior to flow cytometry (Gallios, Beckman Coulter). 
12	  
	  
	  
	  
 
FLIM-­‐based	  FRET	  Assay	  	  
 For the image series and spectra measurements, a Leica TCS SP5-X-AOBS microscope 
equipped with an acousto-optical beamsplitter and WLL lasers was used with a ×40/0.8 water 
immersion objective. Temporal histogram depicting the AlexaFluor 488 fluorescence lifetime 
was obtained by a biexponential fit of the fluorescence decay. The decay analysis by time-
correlated single photon counting was performed using the SPCImage software 
(Becker&Hickl).  
  
Cell	  apoptosis	  assays	  
 After transient transfection with empty vector or with 3-OST3A-HA cDNA and with 
siRNA control or siRNA 3-OST3A in the case of SKBR3 cells for 48 h, cells were stained 
with AlexaFluor 488-conjugated annexin V and propidium iodide (PI) dyes (Invitrogen). The 
externalization of phosphatidylserine (PS) and the permeability to PI were evaluated by flow 
cytometry. A TUNEL test was also performed on MCF-7 cells transfected with empty vector 
or with 3-OST3A-HA cDNA. 
	  
Cell	  proliferation	  assay	  
 Twenty four hours after transfection with 3-OST3A-HA cDNA, and with siRNA 3-
OST3A and corresponding controls, MCF-7, MDA-MB-231 and SKBR3 cells were 
harvested each day during a 4-day period and cell proliferation was evaluated by measuring 
DNA content. Cell proliferation was also assessed 2 days following transient transfection in 
SKBR3 cells treated with 0, 20 and 40 µg/mL trastuzumab kindly provided by Dr. Catherine 
Vallance (Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France). 
 
In	  vivo	  mouse	  xenograft	  tumor	  model	  	  
 Experiments were performed in 6-week-old female severe combined immunodeficient 
(SCID) mice. MCF-7 cells stably expressing 3-OST3A-HA or transfected with pcDNA 
empty vector were subcutaneously implanted into the animals. 5×106 cells were injected into 
each mouse (four mice/group for each independent experiment). The tumor growth was 
assessed weekly using a Vernier caliper. The experiment was conducted twice using two 
different engineered MCF-7 cell lines denominated 3-OST3A-A and -B, and pcDNA-A and -
B, respectively. 
 
Breast	  tumor	  sample	  analyses	  
 3-OST3A mRNA expression was analyzed in a cohort of 117 primary breast tumors 
collected at Ninewells Hospital, Dundee, UK from Caucasian women with no previous 
treatment or operation (Tayside Tissue Bank (TTB), Dundee, UK). Informed consent was 
obtained from all patients and ethical approval was received from TTB (REC Reference: 
07/S1402/90) under delegated authority from the Local Research Ethics Committee. Breast 
cancer overall survival (overall survival) and breast cancer-specific disease free survival 
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(disease free survival or cancer recurrence) were considered. Non-breast cancer deaths 
(women died from other causes than breast cancer) were censored. The characterization of 
classical molecular markers was conducted as previously described.45 Histological tumor 
grade was according to Bloom et al.46, ER status according to Quickscore method47 and 
HER2+ scoring according to Purdie et al.48  
 
Statistical	  analysis	  	  
 Data were analyzed using Prism software (GraphPad, San Diego, CA) and are expressed 
as mean±SEM of two replicates in at least three independent experiments. One-way ANOVA 
and Tukey’s post-hoc test were used for analysis of data from cell proliferation and FLIM 
assays. Two-way ANOVA and Bonferroni post-hoc tests were used to calculate differences 
in tumor growth. Paired Student’s t test was used to calculate P values for all other 
experiments. P value <0.05 was considered significant. 
 Statistical univariate analyses (Kaplan-Meier and Log Rank test) of clinical data were 
performed using SPSS software (SPSS, version 21.0) followed by multivariate analyses of 
Cox’s proportional hazards regression model (CR) with associated Hazard Ratios (HR) 
utilizing the backwards step-wise elimination method. 
Experimental Procedures are detailed in the Supplementary Materials and Methods section. 
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Figure	  Legends	  
	  
Figure	   1.	  3-­‐OST3A	   gene	   expression	   is	   regulated	   by	  DNA	  methylation	   and	   histone	   deacetylation	   in	  
breast	  cancer	  cells.	  A,	  3-­‐OST3A	  mRNA	  expression	  level	  is	  differentially	  repressed	  in	  breast	  cancer	  cell	  
lines	   representative	   of	   different	   subtypes	   of	   tumors.	   RT-­‐qPCR	   was	   performed	   using	   gene-­‐specific	  
primers,	   expression	   level	   was	   normalized	   to	   RP29,	   and	   mRNA	   level	   in	   breast	   cancer	   cell	   lines	   is	  
expressed	   relative	   to	   MCF-­‐10A	   control	   cells	   (set	   to	   1).	   **P<0.01,	   ***P<0.001,	   n=3.	   B,	   the	  
methylation	   profile	   of	   the	   proximal	   promoter	   region	   (5’)	   and	   first	   exon	   (3’)	   of	   3-­‐OST3A	   shows	  
hypermethylation	  in	  all	  cell	  lines	  but	  SKBR3.	  The	  number	  of	  methylated	  and	  non-­‐methylated	  sites	  in	  
the	   regions	   of	   interest	   (shown	   in	   Fig.	   S1)	   is	   indicated	   by	   hatched	   and	   empty	   bars,	   respectively.	  
Results	   are	   the	   mean	   from	   sequencing	   data	   of	   at	   least	   3	   independent	   clones.	   C,	   effect	   of	   the	  
DNAmethyltransferase	  inhibitor	  Aza,	  and	  of	  the	  histone	  deacetylase	  inhibitor	  TSA	  on	  3-­‐OST3A	  mRNA	  
expression	   level	   indicate	   epigenetic	   mechanisms	   involving	   DNA	   methylation	   and	   histone	  
deacetylation.	  MCF-­‐7	   (left	  panel)	  or	  MDA-­‐MB-­‐231	  cells	   (right	  panel)	  were	   treated	  with	  Aza	  or	  TSA	  
alone,	  or	  with	  both	  drugs.	  RT-­‐qPCR	  was	  performed	  as	  described	  in	  panel	  A.	  **P<0.01,	  ***P<0.001,	  
n=3.	  
	  
Figure	  2.	  Distinct	  epigenetic	  marks	  are	  associated	  with	  the	  3-­‐OST3A	  gene	  in	  breast	  cancer	  cells.	  A,	  a	  
representative	   map	   of	   the	   3-­‐OST3A	   gene	   with	   ChIP-­‐PCR	   primers	   indicated	   below.	   Three	   sets	   of	  
primers	   (p1-­‐p3)	   covering	   the	   CpG	   island	   of	   the	   3-­‐OST3A	   gene	   were	   used	   for	   PCR	   amplification.	  
Location	  to	  TSS,	  p1:	  -­‐347	  to	  -­‐129;	  p2:	  +216	  to	  +393;	  p3:	  +468	  to	  +605.	  Amount	  of	  (B)	  DNMT	  isoforms,	  
(C)	  H3K4me3,	  H3K9me3	  and	  H3K27me3	  marks,	   (D)	   EZH2	  and	  SUZ12	  of	  PRC2	   complex,	   (E)	  HDAC1,	  
MeCP2	  and	  Sin3A	   recruited	  at	   the	  3-­‐OST3A	  gene	  using	   specific	   antibodies	  was	   compared	   to	   input	  
(about	  2%	  total	  chromatin)	  and	  IgG	  negative	  control	   in	  MCF-­‐10A,	  MCF-­‐7	  and	  MDA-­‐MB-­‐231	  cells.	  F,	  
schematic	   representation	   of	   chromatin	   regulators	   at	   the	   3-­‐OST3A	   gene.	   In	  MCF-­‐7	   cells,	   DNMT3B,	  
EZH2	  and	  H3K27me3	  mediates	  moderate	  transcriptional	  repression	  independently	  from	  MeCP2	  and	  
HDAC1,	  while	   in	  MDA-­‐MB-­‐231,	  DNMTs	  are	  closely	  connected	   to	  HDAC1	  via	  MeCP2	  and	  Sin3A	   in	  a	  
strong	  repressive	  complex.	  
	  
Figure	   3.	   3-­‐OST3A	   expression	   or	   silencing	   produces	   contrasting	   effects	   on	   cell	   proliferation	   in	  
different	   breast	   cancer	   cells.	  A,	   cell	   proliferation	   assessed	   in	   breast	   cancer	   cell	   lines	   1	   to	   5	   days	  
following	  transient	  transfection	  with	  empty	  pcDNA	  vector	  (control)	  or	  3-­‐OST3A-­‐HA	  cDNA	  (3-­‐OST3A)	  
was	   reduced	   in	   MCF-­‐7	   and	   MDA-­‐MB-­‐231	   but	   enhanced	   in	   SKBR3	   cells.	   3-­‐OST3A	   expression	   was	  
monitored	  by	  immunoblot	  analysis	  using	  anti-­‐HA	  antibodies	  (shown	  below	  histograms).	  SKBR3	  cells	  
transfected	   with	   siRNA	   control	   or	   3-­‐OST3A	   siRNA	   showed	   reduced	   cell	   growth	   in	   depleted	   cells.	  
*P<0.05,	   **P<0.01,	   ***P<0.001,	   n=4.	  B,	   cell	   growth	   rate	   was	   assessed	   2	   days	   following	   transient	  
transfection	  with	  3-­‐OST3A-­‐HA	  cDNA,	  siRNA	  and	  corresponding	  controls	  in	  SKBR3	  cells,	  as	  in	  panel	  A,	  
and	  treated	  with	  0,	  20	  and	  40	  µg/mL	  trastuzumab.	  The	  antiproliferative	  effect	  of	  trastuzumab	  was	  
enhanced	  upon	  3-­‐OST3A	  expression	  whereas	   it	  was	  suppressed	   in	  SKBR3-­‐depleted	  cells.	  **P<0.01,	  
***P<0.001,	  n=4.	  	  	  
	  
Figure	  4.	  3-­‐OST3A	  expression	  triggers	  apoptotic	  events	   in	  MCF-­‐7	  cells	  and	  retards	  tumor	  growth	  in	  
xenografted	   mice.	   A,	   Annexin	   V	   assay	   in	   MCF-­‐7	   cells	   transiently	   transfected	   with	   empty	   vector	  
(control)	   or	   3-­‐OST3A	   cDNA	   (3-­‐OST3A)	   by	   FACS	   analysis	   (left	   panel).	   Quantitative	   analysis	   of	   early	  
(annexin	  V+/PI-­‐,	  right	   low	  square)	  and	  late	  (annexinV+/PI+,	  right	  upper	  square)	  stages	  of	  apoptosis	  
shows	   increased	   percentage	   of	   apoptotic	   cells	   upon	   3-­‐OST3A	   expression	   (right	   panel).	   **P<0.01,	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n=3.	   B,	   immunoblot	   analysis	   of	   apoptotic	   proteins	   in	   MCF-­‐7	   cells	   transfected	   with	   empty	   vector	  
(control)	   or	   3-­‐OST3A	   cDNA	   (3-­‐OST3A).	   Quantitative	   analysis	   of	   protein	   expression	   using	   Image	   J	  
software	   shows	   increased	   Bax	   and	   decreased	   Bcl2	   level,	   and	   increased	   cleaved	   caspase	   9	   and	  
cleaved	   PARP.	   Expression	   level	   of	   each	   protein	   is	   expressed	   relative	   to	   control	   cells	   (set	   to	   1).	  
**P<0.01,	   n=3.	  C,	   TUNEL	  assay	   in	  MCF-­‐7	   cells	   transfected	  with	  empty	   vector	   (control)	   or	   3-­‐OST3A	  
cDNA	   (3-­‐OST3A)	   by	   dUTP	   labelling	   shows	   increased	   DNA	   fragmentation.	   Quantitative	   analysis	   of	  
fragmented	   DNA	   was	   performed	   using	   Image	   J	   software.	   Level	   of	   fragmented	   DNA	   is	   expressed	  
relative	  to	  control	  cells	  (set	  to	  1).	  ***P<0.001,	  n=3.	  Scale	  =	  25	  µm.	  D,	  3-­‐OST3A	  expression	  in	  pcDNA	  
(Control-­‐A	  and	  B)	  and	  3-­‐OST3A-­‐HA	  (3-­‐OST3A-­‐A	  and	  B)	  stably	  transfected	  MCF-­‐7	  cells	  were	  analyzed	  
by	  immunoblotting	  after	  10	  passages.	  E	  and	  F,	  the	  effect	  of	  3-­‐OST3A	  in	  3-­‐OST3A-­‐A	  and	  -­‐B	  MCF-­‐7	  cell	  
lines	  compared	  with	  tumors	  formed	  in	  mice	  implanted	  with	  Control-­‐A	  and	  -­‐B	  shows	  delayed	  tumor	  
formation.	  Controls	  are	  represented	  by	  black	  solid	  circles	  and	  3-­‐OST3A-­‐expressing	  cells	  by	  red	  solid	  
circles.	  *P<0.05,	  **P<0.01,	  n=3	  or	  4.	  	  
Figure	   5.	   3-­‐OST3A	   expression	   impairs	   FGF-­‐7	   cell-­‐surface	   binding	   via	   FGF-­‐7-­‐HS	   interactions	   and	  
regulates	  FGF-­‐7-­‐dependent	  signaling	  in	  MCF-­‐7	  cells.	  A,	  confocal	  immunofluorescence	  microscopy	  of	  
FGF-­‐7	  cell-­‐surface	  binding	  on	  MCF-­‐10A	  cells	  transfected	  by	  siRNA	  control	  or	  siRNA	  3-­‐OST3A	  (upper	  
panel)	  	  and	  on	  MCF-­‐7	  cells	  transfected	  with	  empty	  vector	  (control)	  or	  with	  3-­‐OST3A	  cDNA	  (3-­‐OST3A)	  
(lower	  panel).	  Cells	  were	  doubled-­‐stained	  for	  bound	  FGF-­‐7	  (green)	  and	  nucleus	  (blue).	  A	  single	  cell	  is	  
presented	   in	   inset.	  B,	   semi-­‐quantitative	   analysis	   of	   the	   fluorescence	   intensity	   from	   panel	   A	   using	  
Image	   J	   software	   shows	   increased	   FGF-­‐7	   binding	   in	   3-­‐OST3A	   siRNA	   depleted	   MCF-­‐10A	   cells	   and	  
reduced	  FGF-­‐7	  binding	  upon	  3-­‐OST3A	  expression	  in	  MCF-­‐7	  cells.	  ***P<0.001,	  n=3.	  C,	  flow	  cytometry	  
of	   FGF-­‐7	   cell-­‐surface	   binding	   performed	   on	   cells	   transfected	   as	   in	   panel	   A.	   Upper	   panel	   shows	  
increased	  fluorescence	  signal	  in	  MCF-­‐10A	  transfected	  by	  siRNA	  3-­‐OST3A	  (green)	  compared	  to	  siRNA	  
control	  (white).	  Lower	  panel	  shows	  reduced	  fluorescence	  signal	  in	  MCF-­‐7	  transfected	  with	  3-­‐OST3A	  
cDNA	  (green)	  compared	  with	  empty	  vector	  (white).	  D,	  FRET	  analysis	  of	  FGF-­‐7-­‐HS	  interactions	  using	  
anti-­‐FGF-­‐7-­‐AlexaFluor	  488	  antibodies	   as	   fluorescence	  donor,	   in	   the	  presence	  of	   anti-­‐HS-­‐AlexaFluor	  
555	  antibodies	  as	  acceptor.	  Quantification	  of	   FRET	  by	  FLIM	  showing	   the	  distribution	  of	   lifetime	  of	  
the	   donor	   from	   0.25	   (orange,	   FRET++)	   to	   2.1	   ns	   (blue,	   FRET-­‐)	   indicates	   more	   FRET	   positive	   cells	  
(green)	   in	   control	   compared	   to	  3-­‐OST3A	  cells.	  E,	   lifetime	  decay	   showed	  higher	  average	   lifetime	  of	  
donor	  in	  3-­‐OST3A	  cells	  compared	  to	  HA-­‐negative	  and	  empty	  vector	  transfected	  cells	  (shown	  in	  Table	  
1	  and	  Fig.	  S4).	  F,	  G,	  H,	  3-­‐OST3A	  expression	  regulates	  FGF-­‐7-­‐mediated	  signaling.	  3-­‐OST3A	  transfected	  
MCF-­‐7	   cells	   were	   serum-­‐starved	   for	   24	   h	   and	   treated	   with	   FGF-­‐7.	   Lower	   panels	   show	   a	  
representative	   immunoblot	   of	   cell	   lysates	   performed	  with	   (F)	   anti-­‐phospho-­‐AKT	   and	   anti-­‐AKT,	   (G)	  
anti-­‐phospho-­‐ERK1/2	   and	   anti-­‐ERK1/2,	   and	   (H)	   anti-­‐phospho-­‐p38	   and	   anti-­‐p38	   antibodies.	   The	  
relative	   intensity	  of	   immunoreactive	  bands	  of	  phosphorylated	  versus	   total	  protein	  shown	   in	  upper	  
panels.	  *P<0.05,	  n=3.	  	  
Figure	   6.	   3-­‐OST3A	   expression	   depends	   on	   the	   breast	   cancer	   subtype	   and	   determines	   clinical	  
outcome.	  A,	  multi-­‐variable	  Kruskal-­‐Wallis	  non-­‐parametric	  test	  was	  used	  to	  analyse	  the	  association	  
between	  the	  breast	  cancer	  subtype	  (triple	  negative	  (TN,	  ER-­‐,PR-­‐,HER2-­‐),	  luminal	  B	  (lumB,	  ER+,	  PR-­‐,	  
HER2-­‐),	   luminal	   A	   (lumA,	   ER+,PR+,HER2-­‐),	   HER2+	   (HER2+	   regardless	   of	   ER	   and	   PR	   status))	   and	   3-­‐
OST3A	  expression	  level	  determined	  by	  RT-­‐qPCR.	  B,	  non-­‐parametric	  Kaplan-­‐Meier	  plots	  shows	  that	  
disease-­‐free	   survival	   (left)	   and	   cancer-­‐related	   survival	   (right)	   in	   HER2+	   patients	   was	   significantly	  
lower	  in	  3-­‐OST3A	  positive	  tumors.	  	  C,	  non-­‐parametric	  Kaplan-­‐Meier	  plots	  of	  binary	  variable	  (3ost,	  S,	  
LN)	   in	   relation	   to	   disease-­‐free	   survival	   (left)	   and	   cancer-­‐related	   survival	   (right)	   shows	   that	   71%	  
positive	  patients	  suffered	  from	  recurrence	  and	  among	  them	  60%	  from	  death.	  Censored	  cases	  are	  
shown	  on	  the	  curves.	  Log-­‐rank	  analyses	  and	  P	  values	  are	  indicated.	  The	  number	  of	  patients	  (n)	  and	  
events	  (e)	  are	  indicated.	  
20	  
	  
	  
	  
	  
Table 1. Lifetime of FGF-7-AlexaFluor 488 in MCF-7 cells 
Condition Lifetime (ns) 
3-OST3A cDNA    0.95 ± 0.07*† 
HA-   0.36 ± 0.12* 
Control cDNA  0.42 ± 0.10 
 
3-OST3A cDNA, HA-negative (HA-) and control cDNA correspond to regions analyzed in 3-OST3A 
cDNA-transfected cells expressing 3-OST3A-HA, in 3-OST3A cDNA-transfected cells lacking 3-
OST3A-HA expression and in empty vector-transfected cells, respectively, as in Fig. S4A and B. Data 
are mean ± SEM. *P<0.05 vs. control cDNA, †P<0.05 vs. HA-, n=3. Statistical analysis was 
performed using one-way ANOVA with Tukey’s post-hoc test. 
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Table 2. Multivariate Cox’s regression analysis on primary HER2+ breast cancer 
   Omnibus test of model coefficient   
 Itr. Predictor χ2 df I value HR 95% CI 
 
Disease-free survival 1 (3ost, S, LN) 23.233 
 
1 2.10-6 
 
27.3 3.6     207.7 
 
Overall survival 1 (3ost, S, LN) 14.354 1 2.10-4 
 
117.1 0.41   3.105	  
 
Number of HER2+ patients, 49. The clinico-pathological parameters were: presence of lymph node 
metastasis (LN), tumor size (S), 3-OST3A (3ost) and the combined binary variable (3ost, S, LN). HR, 
hazard ratio; CI, confidence interval. 	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Figure S1. Hypermethylation of 3-OST3A gene in breast cancer cell lines. A, analysis of the human 3-OST3A gene 
sequence for the presence of a CpG island (shown in blue) using MethPrimer software. Two sequences were analyzed i.e. 
the proximal promoter region (indicated as 5’ region) and a region containing the first transcribed exon (indicated as 3’ 
region), located at -360 to +120 and at +262 to +746 to the TSS, respectively. Red vertical lines below the diagram indicate 
the CpG sites, the TSS is marked by a black curved arrow and the ATG is shown by an arrow. B, methylation profile of the 
two regions of interest in MCF-10A, SKBR3, MCF-7, BT-474, T-47D, MDA-MB-231, MDA-MB-453 and MDA-MB-468 cells. 
Circles represent the total number of CpG sites in the 5’ and 3’ regions (46 and 54, respectively). Open and solid circles 
depict the unmethylated and methylated CpG sites, respectively. Results show bisulfite sequencing of 3 different clones. 
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Figure S2. Effect of 3-OST3A overexpression and knockdown on apoptosis determined by Annexin V flow 
cytometry assay. Forty-eight hours following transient transfection with 3-OST3A cDNA or with siRNA 3-
OST3A and controls, cells were analyzed by flow cytometry. Representative profile from 10,000 events per 
sample shows Annexin V‐AlexaFluor 488 staining  (x axis) and PI staining (y axis). Cells were classified as 
healthy cells (Annexin V−, PI−, left lower square), early apoptotic cells (Annexin V+, PI−, right lower square), 
late apoptotic cells (Annexin V+, PI+, right upper square), and damaged cells (Annexin V−, PI+, left upper 
square). Quantitative analysis of early (annexin V+/PI‐) and late (annexinV+/PI+) stages of apoptosis was 
performed. Data are expressed as percentage of apoptotic (early and late) to total number of cells.  
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Figure S3. The tumor suppressor effect of 3-OST3A cDNA stably transfected in MCF-7 cells (3-
OST3A-A and -B) was evaluated in SCID mice compared with tumors formed from MCF-7 cells stably 
transfected with their empty vector (Control-A and -B). Mice were injected with 5×106 control cells 
(black solid and dotted lines) or 3-OST3A expressing cells (red solid and dotted lines) and tumor size 
was measured up to 14 and 20 weeks in two separate experiments (panels A and B). In experiment 
shown in panel A, one mouse in control group did not develop any tumor and was omitted from the 
figure.  
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Figure S4. Restoration of 3-OST3A expression in MCF-7 cells inhibits FGF-7-HS interactions. A, Confocal 
microscopy analysis of FRET between FGF-7 and HS in empty vector (control) and 3-OST3A-HA cDNA 
stably transfected MCF-7 cells (3-OST3A). Upper panels show fluorescence signal of donor excited at 488 
nm in the presence of acceptor. Middle panels show fluorescence signal of the acceptor produced by 
energy transfer from the donor. Lower panels show 3-OST3A-HA positive cells in red color detected by 
anti-HA and AlexaFluor 633 conjugated antibodies. Scale bar = 30 µm. B, Fluorescence spectra (lambda-
scan) analysis from two regions of interest (green and purple circles in panel C of Figure S5A). Specifically, 
in 3-OST3A cDNA transfected cells, green and purple curves correspond to a HA negative (HA-) and a 3-
OST3A-HA expressing (HA+) cell, respectively. C, lifetime decay experiments showing the changes of the 
lifetime average of the donor in 3-OST3A-transfected cells compared to HA-negative and empty vector 
transfected cells. 
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Figure S5. FGF-7-dependent signaling in MCF-7 cells. MCF-7 cells stably transfected with 
empty vector as control were serum-starved for 24 h and then stimulated with FGF-7 at the 
indicated concentrations. The lower panel shows a representative immunoblot analysis of cell 
lysates performed with (A), anti-phospho-ERK1/2 (Thr202/Tyr204) and anti-ERK1/2, (B), 
anti-phospho-AKT (Ser473) and anti-AKT. (C), anti-phospho-p38 (Thr180/Tyr182) and anti-
p38. The upper panel shows the relative intensity of immunoreactive bands of 
phosphorylated versus total protein, n=3. * P < 0.05  
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Figure S6. Schematic representation of the effect of 3-OST3A expression on HSPG-dependent 
FGF-7/FGFR2IIIb signaling axis. In MCF-7 cells, 3-OST3A gene expression is repressed upon 
DNA methylation and histone modifications such as H3K27me3. Upon cDNA transfection, 
restored expression results in modification of the interactions between FGF-7 and HS chains, 
leading to the modulation of downstream signaling pathway involving ERK, AKT and p38 that 
contribute to the anti-proliferative and pro-apoptotic properties of 3-OST3A in cancer cells.  
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Figure S7. Association between 3-OST3A expression level and HER2+ breast cancer recurrence. A, Receiver 
Operating Characteristic (ROC) curve for cancer recurrence in HER2+ breast tumors in association with 3-
OST3A level. The optimal cut-off was determined by Youden Index corresponding to the greatest vertical 
distance between ROC curve and the diagonal line. This index cut-off value that maximized the sum of 
sensitivity and specificity was determined for 3-OST3A expression level in HER2+ breast tumors. B, Tumors 
expressing a ratio of 3-OST3A/Tata Binding Protein (TBP) mRNA superior to 0.1222683 were defined as 3-
OST3A positive, while tumors expressing a ratio of 3-OST3A/TBP mRNA ranging from 0 to 0.1222682 were 
defined as 3-OST3A negative.  
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Figure S8. Kaplan-Meier survival curves of patients with breast cancer based on different pathological markers. A, Kaplan-
Meier disease free survival curves of patients with breast cancer based on subtypes (luminal A, lumA; luminal B, lumB; triple 
negative, TN and HER2+). Number of breast tumors analysed, n=117. B, Kaplan-Meier disease free survival curves of 
HER2+ breast cancer patients correlated with tumor size. C, Kaplan-Meier disease free survival curves of HER2+ breast 
cancer patients correlated with presence of lymph node metastatis (invaded lymph node). Censored cases are shown on the 
curves. Log-rank analyses, P values, number of patients (n) and events (e) are indicated.  
Supplementary	  Materials	  and	  Methods	  
	  
Cell	  culture,	  drug	  treatment	  and	  gene	  transfection	  	  
 SKBR3, MCF-7, BT-474, MDA-MB-231, MDA-MB-453 and MDA-MB-468 cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) 4.5 g/L glucose supplemented 
with 10% (v/v) fetal bovine serum (FBS, Gibco), penicillin (1 U/mL)/streptomycin (1 
µg/mL), L-glutamine (2 mM) and non-essential amino acids (NEAA, 0.1 mM). T-47D cells 
were cultured in RPMI-1640 Medium, supplemented with 10% (v/v) FBS, penicillin (1 
U/mL)/streptomycin (1 µg/mL), L-glutamine (2 mM) and bovine insulin (0.2 U/mL). MCF-
10A cells were maintained in DMEM-F12 medium, supplemented with 5% (v/v) donor horse 
serum, penicillin (1 U/mL)/streptomycin (1 µg/mL), 1% (v/v) L-glutamine (2 mM), epidermal 
growth factor (EGF, 20 ng/mL), insulin (10 µg/mL), cholera toxin (100 ng/mL) and 
hydrocortisone (0.5 µg/mL). All cell lines were grown at 37°C in a 5% CO2 incubator under 
humidified atmosphere. MCF-7 and MDA-MB-231 cells were treated with 5-aza-2’-
deoxycytidine (Aza, Sigma) at 2 and 4 µM concentration for 9 days, while controls were 
exposed to vehicle only (Phosphate Buffered Saline, PBS). During drug exposure, cells were 
passaged twice and medium containing Aza or vehicle was changed every 2 days. 
Trichostatin A (TSA, Sigma) at a concentration of 300 nM, or vehicle only 
(dimethylsulfoxide, DMSO) was added to cultures 24 h before the end of the experiment.   
 The plasmid pcDNA3.1(+)-3-OST3A-hemagglutinin (HA) or pcDNA3.1(+) was 
transiently or stably transfected into MCF-7, MDA-MB-231 and SKBR3 cells. All transient 
transfections were performed by electroporation following manufacturer’s recommendations 
(NucleofectorTM Protocols, Lonza). For stable expression, the transfection protocol was 
optimized using pEGFP-N1 vector (Clontech). Briefly, 3×105 cells/well were seeded onto 6-
well plates 24 h before transfection using 2 µg plasmid DNA and 15 µL Exgen 500 reagent 
(Euromedex) per well. Selection of stable transfectants was performed using 1.5 mg/mL 
geneticin (G418, Gibco). Resistant colonies were isolated and expression of 3-OST3A-HA 
recombinant protein in the individual colonies was verified by western blotting using anti-HA 
antibodies (Table S7). Two colonies stably expressing 3-OST3A (A and B) or stably 
transfected with pcDNA (A and B) were selected for xenograft experiments.  
 siRNAs against 3-OST3A were designed and synthesized by Eurogentec. Two 3-OST3A 
siRNAs (Table S8) and a negative control siRNA (Qiagen) were transfected in SKBR3 cells 
by electroporation following the manufacturer’s recommendations (NucleofectorTM Protocols, 
Lonza). siRNA inhibition efficiency was verified by RT-qPCR analysis of 3-OST3A mRNA 
level (>80%) using primers listed in Table S9, and by immunodetection of the recombinant 3-
OST3A-HA protein using anti-HA antibodies.   
 
RT-­‐qPCR	  analysis	  	  
 Purified RNA extracted from cultured cells was reverse-transcribed to cDNA using the 
SuperScript® VILO™ cDNA synthesis kit (Invitrogen). qPCR reactions were performed 
using SYBR Green I (Qiagen) in a LightCycler® system (Roche). Specificity of the 
amplification was verified using melting curve analysis. The 2-ΔΔCt method was used to 
determine relative gene transcript levels normalized to RP29 reference gene. The primers used 
are listed in Table S9. Conditions for the qPCR reaction were 94°C for 15 min followed by 40 
cycles at 94°C for 15 s, 55°C (RP29) or 60°C (3-OST3A) for 1 min, and ending with a final 
step of 15 s at 94°C, 1 min at 60°C and 15 s at 94°C corresponding to melt curve stage. 
For tumor analysis, approximately 10 mg of tissue (> 40% of tumor cells) was homogenized 
in 75 µL of QIAzol lysis reagent (Qiagen) and total RNA was extracted as described above 
(Qiagen). RNA quality was assessed using the BioAnalyzer 2100™ (Agilent Technologies) 
prior to RT-qPCR analysis and all samples with a ratio of 28S/18S < 1.2 were discarded. 
Reverse transcription was performed with 0.5 µg of total RNA, using the cloned AMV 
Reverse Transcription kit (Invitrogen) and cDNA quality was confirmed by PCR 
amplification of actin. Samples for which actin mRNA could not be amplified after 30 cycles 
of PCR were discarded. PCR conditions were as above. 
 
CpG	  island	  identification	  and	  methylation	  status	  analysis	  
 Genomic DNA (gDNA) extracted from MCF-10A, SKBR3, MCF-7, BT-474, T-47D, 
MDA-MB-231, MDA-MB-453 and MDA-MB-468 cells was submitted to bisulfite 
conversion using the EpiTect Bisulfite kit (Qiagen) according to the manufacturer’s 
instructions. Converted gDNA was used for amplification of two regions of interest by 
nested-PCR using sense and antisense primers listed in Table S10. Conditions for the first 
PCR reaction were 94°C for 8 min followed by 20 cycles at 94°C for 30 s, 55°C for 30 s, 
72°C for 30 s, ending with a final extension step of 10 min at 72°C. For the second round of 
PCR, conditions were 94°C for 8 min followed by 35 cycles at 94°C for 30 s, 60°C for 30 s, 
72°C for 30 s, and finally 10 min at 72°C. PCR products were purified and subcloned using 
the TOPO TA® Cloning kit (Invitrogen) and transformed into One Shot® TOP10 competent 
cells (Invitrogen). Plasmid DNA of at least three individual clones was sequenced to identify 
uncovered cytosines within CpG dinucleotides, which correspond to methylated sites. 
 
Chromatin	  immunoprecipitation	  (ChIP)	  assay	  	  
 For the ChIP assay, 1×106 cultured cells were harvested and fixed with 1% (w/v) 
paraformaldehyde for 10 min at room temperature with gently stirring. Glycine buffer (1.25 
M) was added into the mix to stop the cross-linking reaction. The cell pellet was collected and 
sonicated to shear chromatin DNA to an average length of 500 bp-fragments. The input DNA 
was quantified by spectrofluorimetry on a Qubit (Invitrogen) apparatus using Quant-iT 
dsDNA HS Assay kit (Invitrogen). Protein G-coated magnetic beads were incubated with 
primary antibodies (listed in Table S11) at 4°C for at least 2 h, prior to incubation with 
chromatin DNA at 4°C overnight. Crosslinking was reversed by overnight incubation at 65°C, 
and ChIP DNA product was purified and isolated using the IPure kit (Diagenode) for 
subsequent PCR reaction. The PCR primers (Table S12) were designed by Premier Primer 5.0 
software to amplify 3 adjacent regions, -347/-129, +216/+393 and +468/+605 to the TSS of 
human 3-OST3A gene.  
 
Protein	  extraction	  and	  western	  blotting	  
 Cells cultured in 6-well plates were harvested and lysed in 100 µL of NP-40 lysis buffer 
containing 1% (v/v) NP-40, 20 mM Tris-HCl (pH 8.0), 137 mM NaCl, 10% glycerol, 2 mM 
EDTA supplemented with protease and phosphatase inhibitor mixture (Roche). Protein 
concentration was determined by using a Bradford protein assay kit (Biorad). Lysates 
containing 20 µg of protein were subjected to sodium dodecyl sulfate (SDS)-PAGE on 10% 
(w/v) polyacrylamide gels. Proteins were transferred onto Immobilon-P® polyvinylidene 
(PVDF) membrane (Millipore) and incubated in the presence of primary antibodies listed in 
Table S7. Following incubation with anti-mouse or anti-rabbit peroxidase conjugated 
secondary antibodies (Cell Signal Technology), proteins were visualized by the Enhance 
Chemiluminescence (ECL) western blot detection kit (Santa Cruz).  
 
Cell	  proliferation	  assay	  	  
 Cells transfected with 3-OST3A-HA cDNA or with siRNA 3-OST3A and corresponding 
controls were seeded onto 24-well plates at a density of 2×104 cells per well for MCF-7 and 
MDA-MB-231 cells and 4×104 cells per well for SKBR3 cells. Twenty-four hours after 
transfection, cells were harvested each day during a 4-day period by scraping in 50 µL lysis 
buffer (1% (w/v) SDS-PBS). Cell proliferation was evaluated by measuring the DNA content 
in each sample by spectrofluorimetry using the Quant-iT dsDNA HS Assay kit (Invitrogen). 
The proliferation assay was also performed on SKBR3 cells treated with 0, 20 and 40 µg/mL 
of trastuzumab 24 h after transfection.  
 
Annexin	  V	  flow	  cytometry	  cell	  apoptosis	  assays	  
 Cells transfected with 3-OST3A-HA cDNA, and with siRNA 3-OST3A and corresponding 
controls were seeded onto 6-well plates at a density of 1.5×105 cells per well. 48 h following 
transfection, cells were detached by cell dissociation enzyme-free PBS-based buffer (Gibco), 
washed 3-times in PBS, and stained with AlexaFluor 488-conjugated annexin V and 
propidium iodide (PI) dyes (Invitrogen). The externalization of phosphatidylserine (PS) and 
the permeability to PI were evaluated by flow cytometry by collecting data from 10,000 
events per sample.  
 
TUNEL	  imaging	  assay	  
 MCF-7 cells were transfected with empty vector (control) or with 3-OST3A-HA cDNA by 
electroporation and seeded onto Lab-Tek chambers at a density of 2×104 cells per well. Forty-
eight hours after transfection, cells were prepared to TUNEL (terminal deoxynucleotidyl 
transferase-dUTP nick and labeling) assay following the manufacturer’s recommendations 
(Click-iT® TUNEL AlexaFluor® Imaging Assay, Invitrogen) to detect fragmented DNA. 
Cells were washed with PBS and fixed in 4% (w/v) paraformaldehyde at RT for 15 min and 
permeabilized with 0.25% (w/v) Triton-X 100 in PBS at RT for 20 min, washed 2-times with 
deonized water before to proceed to TdT (terminal deoxynucleotidyl transferase) reaction. 
Cells were incubated with TdT reaction buffer at RT for 10 min and then with TdT reaction 
cocktail containing TdT reaction buffer, EdUTP and TdT for 60 min at 37°C. Cells were 
washed 2-times with 3% (w/v) BSA-PBS for 2 min before to proceed to Click-iT reaction. 
Cells were incubated with Click-iT reaction cocktail containing the Click-iT reaction buffer 
(which contains AlexaFluor 594 azide) and the Click-iT® reaction buffer additive at RT for 
30 min protected from light, washed with 3% (w/v) BSA-PBS for 5 min. In parallel, a 
positive control was performed using DNase I which generates strand breaks in the DNA. 
Images were analyzed by confocal laser scanning microscopy on a Leica TCS SP5-X-AOBS 
apparatus. 
 
In	  vivo	  mouse	  xenograft	  tumor	  model	  
 The animal protocol was approved by the regional Ethical Committee (Institut Pasteur, 
Lille, France). Engineered MCF-7 cell lines stably transfected with 3-OST3A-HA or pcDNA 
vector were inoculated subcutaneously into 6-week-old female SCID mice. 5×106 cells were 
injected into each mouse, and four mice were used by group for each individual experiment. 
The tumor size was assessed once per week using external measurement of the two largest 
orthogonally diameters using a Vernier caliper. Tumor volume was calculated using the 
formula V = a*b2/2 where “a” is the largest measured diameter and “b” the shortest. For 
ethical considerations, animals were euthanized when the tumor diameters exceeded 1 cm and 
had about 1 g of tumor weight (i.e. 5% of animal weight).	  The protocol was repeated twice 
using two independent 3-OST3A- and control pcDNA-engineered cell lines. 
 
Confocal	  microscopy	  observation	  of	  FGF-­‐7	  cell-­‐surface	  binding	  
 Cells cultured in Lab-Tek chambers (Thermo-scientific) were serum-starved for 24 h, 
incubated with freshly prepared medium containing recombinant human FGF-7 (R&D 
system, 0.5 ng/mL) for 30 min or containing same volume of PBS, rinsed 3-times and fixed in 
4% (w/v) paraformaldehyde at room temperature (RT) for 10 min. After blocking with 5% 
(w/v) bovine serum albumin (BSA)-PBS, cells were incubated with anti-HS antibody (10E4 
epitope, Seikagaku Corp.) in 1% (w/v) BSA-PBS at RT for 45 min, washed 3-times with 
PBS, incubated with AlexaFluor 555-conjugated donkey anti-mouse antibodies (Invitrogen) 
for 45 min, and finally washed with PBS. For FGF-7 visualization, cells were incubated with 
goat anti-human FGF-7 (Santa Cruz) and then AlexaFluor 488-conjugated rabbit anti-goat 
antibodies (Invitrogen). For nucleus staining, cells were permeabilized with a 0.2% (w/v) 
BSA-PBS solution containing 0.1% (w/v) Triton-X 100 at RT for 10 min, washed 3 times 
with PBS, incubated with TOPRO®-3 Iodide (642/661) (Invitrogen) in PBS for 10 min, and 
washed 3 times with PBS before observation. Images were analyzed by confocal laser 
scanning microscopy on a Leica TCS SP5-X-AOBS apparatus. All primary and secondary 
antibodies are listed in Table S7. 
 
FLIM-­‐based	  FRET	  assay	  of	  FGF-­‐7-­‐HS	  interactions	  
 A Leica TCS SP5-X-AOBS microscope equipped with an acousto-optical beamsplitter and 
WLL lasers was used with a ×40/0.8 water immersion objective for image captures and 
spectra measurements. In all cases, excitation wavelength was 488 nm for FRET donor and 
adjusted to minimize the excitation of the acceptor (AlexaFluor 555). Fluorescence lifetime 
measurements were performed with a time-correlated single photon counting technique using 
a WLL laser with a pulse width from 120 fs and a repetition rate of 76 MHz. For lifetime 
imaging in FLIM assay, a SPC-730 TCSPC imaging module (Becker&Hickl, Berlin) was 
interfaced (signals, Pixel Clock, Frame Sync) to the scan controller of the Leica TCS SP5-X-
AOBS laser scanning microscope. Temporal histogram depicting the AlexaFluor 488 
fluorescence lifetime distribution was obtained by a biexponential fit of the fluorescence 
decay and the decay analysis evaluated by time-correlated single photon counting was 
performed using the SPCImage software (Becker&Hickl GmbH).  
 
Flow	  cytometry	  analysis	  of	  FGF-­‐7	  cell-­‐surface	  binding	  	  
 Cells cultured in 6-well plates were treated with FGF-7 as above. Then, 3×105 cells per 
assay were incubated with 3 µg goat anti-human FGF-7 antibodies in 100 µL 0.5% BSA-PBS 
at 4°C for 15 min, washed once with PBS, incubated with AlexaFluor 488-conjugated rabbit 
anti-goat antibodies (Invitrogen) for 15 min, and finally washed once with PBS. Cells samples 
were fixed in 4% (w/v) paraformaldehyde and analyzed on a flow cytometer (Gallios, 
Beckman Coulter). Data from 10,000 events per sample were collected and staining was 
normalized to the control cells (stained with secondary antibodies only).  
 
Clinical	   samples	   and	   tumor	   grade,	   estrogen	   receptor,	   progesterone	   receptor	   and	   HER2	  
status	  analysis	  
 Previously untreated operable primary breast tumors from 117 Caucasian women (age 
range 32-89 years, median age 60 years) with sufficient tumor tissue surplus to diagnostic 
requirements and complete clinical and pathological data, were analyzed (Table S2). Tumor 
tissues were macro-dissected by a specialist breast pathologist and snap frozen in liquid 
nitrogen prior to storage at -80ºC. 
 Immunohistochemical staining was carried out on 4 µm sections of formalin-fixed paraffin 
embedded tumors with the mouse monoclonal anti-estrogen receptor alpha (ER) antibody 
6F11 (Novocastra Laboratories Ltd), progesterone receptor (PR) antibody clone 16, 
(Novocastra Laboratories Ltd) and mouse monoclonal anti-HER2 antibody CB11 (Novocastra 
Laboratories Ltd). Additional analyses were performed according to histological tumor grade 
and tumor size evaluated by a specialist consultant breast pathologist. ER status (as ER 
negative 0-3 versus ER positive 4-18) was determined by the “quickscore” method. Briefly, 
immuno-reactivity scored semi-quantitatively for both the intensity and the proportion of cells 
staining: intensity was given scores 0-3 (no staining = 0, light staining = 1, moderate staining 
= 2, strong staining =3) and proportion was given scores 1-6 (0-4% = 1, 5-20%= 2, 21-40% = 
3, 41-60% = 4, 61-80% = 5, 81-100% = 6). The two scores were then multiplied to obtain the 
final result of 0 - 18.  
 
Statistical	  analysis	  
      Data obtained by clinical studies were subjected to following statistical analysis. The 
difference of 3-OST3A expression level between breast cancer subtypes was evaluated by 
Kruskal-Wallis test (null hypothesis rejected) followed by Mann-Whitney test for pairwise 
comparison. Breast cancer-related survival (abbreviated to overall survival) and breast cancer 
disease free survival (abbreviated to disease free survival or cancer recurrence) were followed 
and non-breast cancer deaths were censored at the time of death. Statistical analysis was 
performed using SPSS software (SPSS version 21.0) for Chi-squared, 2-sided Fisher’s Exact 
Test and Kaplan-Meier analyses. These univariate analyses do test for association between 
variables in a pair-wise manner (e.g. A versus B), but without adjusting for influence exerted 
by other associated variables (e.g. both A and B may be associated with confounding 
variables C, D, E…). To adjust for possible confounding variables, the selected variables were 
interrogated by the multivariate methods of Cox’s proportional hazards regression model 
(CR) with associated Hazard Ratios (HR), both utilizing the backwards step-wise elimination 
method. The results of the univariate and multivariate analyses were consistent, and for clarity 
and brevity only the results of CR and Kaplan-Meier analyses are presented. Throughout the 
analyses, the null hypothesis was rejected at a α level of 10% (P < 0.10), and observations 
considered to be marginal (i.e. unworthy of further analysis) for an α level between 5% and 
10% (0.05 ≤ P < 0.10) and significant at 5% (P < 0.05). The P value represents the probability 
of error that is involved in accepting our observed result as valid. For example, P = 0.05 
indicates a 5% probability for the relation between the variables occurring by chance. 
 
Supplementary	  Tables	  
	  
Table	  S1.	  Classification	  of	  breast	  cancer	  cell	  lines	  
	  
Cell	  line	   Classification	   Immunoprofile	  
MCF-­‐7	   Luminal	  A	   ER+,	  PR+/-­‐,	  HER2-­‐	  
T-­‐47D	   Luminal	  A	   ER+,	  PR+/-­‐,	  HER2-­‐	  
BT-­‐474	   Luminal	  B	   ER+,	  PR+/-­‐,	  HER2+	  
MDA-­‐MB-­‐468	   TN	   ER-­‐,	  PR-­‐,	  HER2-­‐	  
MDA-­‐MB-­‐231	   TN	   ER-­‐,	  PR-­‐,	  HER2-­‐	  
SKBR3	   HER2+	   ER-­‐,	  PR-­‐,	  HER2+	  
MDA-­‐MB-­‐453	   HER2+	   ER-­‐,	  PR-­‐,	  HER2+	  
	  	  
ER,	  estrogen	  receptor;	  HER2+,	  human	  epidermal	  growth	  factor	  receptor	  2;	  PR,	  progesterone	  receptor,	  
TN,	  triple	  negative	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	   	  
Table	  S2.	  Description	  of	  the	  characteristics	  of	  the	  breast	  cancer	  patients	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  	  	  	  	  	  	  	  TBP,	  Tata	  Binding	  Protein	   	  
Variables	   	   Number	  of	  patients	  
primary	  breast	  tumors	   	   117	  
median	  age	  
follow	  up	  
	   61.5	  (range	  28.7-­‐89.1	  years)	  
6.85	  (0.29-­‐13.7	  years)	  
Grade	  
1	  
2	  
3	  
2	  
24	  
91	  
type	   ductal	  others	  
96	  
21	  
clinico-­‐pathological	  	  
subtype	  
TN	  
	  LumA	  
LumB	  
HER2+	  
26	  
27	  
15	  
49	  
size	   <21mm	  ≥21mm	  
24	  
93	  
Invaded	  lymph	  nodes	  	  
(node	  >	  0)	  
none	  
presence	  
53	  
64	  
patient	  outcome	  
disease	  free	  
recurrence	  
alive	  
death	  
90	  
27	  
99	  
18	  
3-­‐OST3A	   ratio	  to	  TBP	  mRNA	   0.191	  (0.0021-­‐0.8842)	  
3-­‐OST3A	  cut-­‐off	  (0.12)	   0	  1	  
48	  
69	  
Table	  S3.	  Univariate	  analysis	  of	  association	  between	  3-­‐OST3A	  expression	  and	  cancer	  recurrence	  
	  
	  
	  
	  
	  
	  
	  
Results	  are	  expressed	  as	  number	  of	  patients,	  Fisher’s	  t	  test,	  P	  <	  0.004	  
	  
	  
	  	  
Table	  S4.	  Univariate	  analysis	  of	  association	  between	  tumor	  size	  and	  presence	  of	  lymph	  node	  
	  
	  
	  
	  
Results	  are	  expressed	  as	  number	  of	  patients,	  Fisher’s	  t	  test,	  P	  <	  0.104	  
	  
	  
	  
Table	  S5.	  Univariate	  analysis	  of	  association	  between	  3-­‐OST3A	  expression	  and	  presence	  of	  lymph	  
node	  
	  
	  
	  
	  
Results	  are	  expressed	  as	  number	  of	  patients,	  Fisher’s	  t	  test,	  P	  <	  0.104	  
	  
	  
	  
Table	  S6.	  Univariate	  analysis	  of	  association	  between	  tumor	  size	  and	  3-­‐OST3A	  expression	  	  
	  
	  
	  
	  
Results	  are	  expressed	  as	  number	  of	  patients,	  Fisher’s	  t	  test,	  P	  <	  0.288	  
	  
	  
	   Recurrence	  
Total	  -­‐	   +	  
3-­‐OST3A	  	  	  	  	  	  	  	  	  -­‐	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  +	  
Total	  
13	  
20	  
33	  
0	  
16	  
16	  
13	  
36	  
49	  
	   Invaded	  Lymph	  node	  
Total	  none	   presence	  
size	  	  	  	  	  	  <	  21	  mm	  	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  ≥	  21mm	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Total	  
8	  
12	  
20	  
5	  
24	  
29	  
13	  
36	  
49	  
	   Invaded	  Lymph	  node	  
Total	  none	   presence	  
3-­‐OST3A	  	  	  	  	  	  	  	  	  -­‐	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  +	  
Total	  
8	  
12	  
20	  
5	  
24	  
29	  
13	  
36	  
49	  
	   Size	  
Total	  <	  21	  mm	   ≥	  21mm	  
3-­‐OST3A	  	  	  	  	  	  	  	  	  -­‐	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  +	  
Total	  
5	  
8	  
13	  
8	  
28	  
36	  
13	  
36	  
49	  
Table	   S7.	   Antibodies	   and	   conditions	   used	   for	   immunoblotting	   and	   immunofluorescence	  
experiments	  
Antibody	   Provider	   Source	   Dilution	  
Human	  phospho-­‐FGFR1-­‐4	  
(Y653/Y654)	  	  
R&D	  systems	  	  
rabbit	  	   1:1000	  	  
Bek	  (C-­‐17)	  or	  FGFR2	  	   Santa	  Cruz	  Biotechnology	   rabbit	  	   1:200	  	  
Phospho-­‐FRS2-­‐α	  (Tyr196)	   Cell	  Signaling	  Technology	   rabbit	   1	  :1000	  
FRS2	   Santa	  Cruz	  Biotechnology	   rabbit	   1	  :200	  
Phospho-­‐AKT	  (Ser473)	  	   Cell	  Signaling	  Technology	  	   rabbit	  	   1:1000	  	  
AKT	   Cell	  Signaling	  Technology	  	  	   rabbit	  	   1:1000	  	  
Phospho-­‐p38	  MAPK	  
(Thr180/Tyr182)	  (D3F9)	  	  
Cell	  Signaling	  Technology	  	  
rabbit	  	   1:1000	  	  
p38	  MAPK	  	   Cell	  Signaling	  Technology	  	   rabbit	  	   1:1000	  	  
Phospho-­‐p44/42	  MAPK	  
(ERK1/2)	  (Thr202/Tyr204)	  
(D13.14.4E)	  	  
Cell	  Signaling	  Technology	  	  
rabbit	  	   1:1000	  	  
P44/42	  MAPK	  (137F5)	  	   Cell	  Signaling	  Technology	  	   rabbit	  	   1:1000	  	  
Poly	  ADP-­‐ribose	  
polymerase	  (PARP)	  
Cell	  Signaling	  Technology	  
rabbit	   1:1000	  
Cleaved	  PARP	  (Asp214)	   Cell	  Signaling	  Technology	   rabbit	   1:1000	  
Bax	  (N-­‐20)	   Santa	  Cruz	  Biotechnology	   rabbit	   1:500	  
Bcl-­‐2	  (C-­‐2)	   Santa	  Cruz	  Biotechnology	   mouse	   1:200	  
Cleaved	  caspase	  9	  
(Asp315)	  
Cell	  Signaling	  Technology	  
rabbit	   1:1000	  
Anti-­‐HA	  	   Sigma-­‐Aldrich	  	  	   rabbit	  	   1:10,000	  	  
β-­‐actin	  	   Sigma-­‐Aldrich	  	   mouse	  	   1:3000	  	  
FGF-­‐7	  (S-­‐20)	  	   Santa	  Cruz	  Biotechnology	  	   goat	  	   1:50	  	  
HS	  (10E4	  epitope)	  	   Seikagaku	  Corporation	  	   mouse	  	   1:50	  	  
GM130	  	   BD	  Transduction	  Laboratories	  	   mouse	  	   1:200	  	  
Anti-­‐mouse	  IgG,	  HRP-­‐
linked	  antibody	  
Cell	  Signalling	  Technology	  	  
horse	   1:2000	  
Anti-­‐rabbit	  	  IgG,	  HRP-­‐
linked	  antibody	  
Cell	  Signaling	  Technology	  	  
goat	  	   1:2000	  
Anti-­‐rabbit	  IgG	  (whole	  
molecule)-­‐alkaline	  
phosphatase	  	  antibody	  
Sigma-­‐Aldrich	  	  	  
rabbit	  	   1:10,000	  
AlexaFluor®488	  rabbit	  
anti-­‐goat	  
Invitrogen	  Life	  Technologies	  	  
rabbit	  	   1:200	  
AlexaFluor®	  555	  donkey	  
anti-­‐mouse	  	  
Invitrogen	  Life	  Technologies	  
donkey	  	   1:200	  	  
AlexaFluor®	  633	  goat	  
anti-­‐rabbit	  
Invitrogen	  Life	  Technologies	  	  
goat	  	   1:500	  	  
	  
	  
Table	  S8.	  Synthetic	  siRNA	  sequences	  used	  for	  RNA	  interference	  experiments	  	  
Gene	   RefSeq	   Sequence	   Size	  (bp)	  
Position	  
Efficiency	  
RNA	  (%)	  	  	  	  	  	  	  	  	  	  Protein	  
3-­‐
OST3A	  
NM_00
6042.1	  	  
Target	  1	  	   5’-CGTCCCTTTACGTCTTCTA-3’  19	   899-­‐917	  	   	  
88.3	  ±	  6.3	  	  	  	  	  	  	  	  	  	  	  	  ND	  Sense	  1	  	   5’-CGUCCCUUUACGUCUUCUA-3’  
Antisense	  1	  	   5’-UAGAAGACGUAAAGGGACG-3’   
  
	   	   Target	  2	   5’-ATCTGGTAGAACTTGAGGT-3’ 19	   1970-­‐1988	   	  
	   	   Sense	  2	   5’-ACCUCAAGUUCUACCAGAU-3’  	   	   71.7	  ±	  4.9	  	  	  	  	  	  	  	  	  	  	  ND	  
	   	   Antisense	  2	   5’-AUCUGGUAGAACUUGAGGU-3’  	   	   	  
Experiments	  were	  performed	  using	   two	   sets	   of	   siRNA	   (1	   and	  2).	   Efficiency	  of	   siRNA	   inhibition	  was	  
evaluated	  using	  MCF-­‐7	  stably	  transfected	  with	  3-­‐OST3A	  cDNA.	  mRNA	  level	  was	  evaluated	  by	  RT-­‐qPCR	  
(mean	   ±	   SEM,	   n=3)	   and	   protein	   expression	   by	   immunoblotting	   using	   anti-­‐HA	   antibodies,	   ND,	   not	  
detectable	  (n=3).	  	  	  
Table	  S9.	  Sequence	  of	  primers	  used	  for	  RT-­‐qPCR	  analysis	  
Gene	   Primers	   Size	  (bp)	   Tm	  (°C)	  
3-­‐OST3A	   Sense	   5'-CAGTGCCCTCTCCACCTC-3’ 108	   60	  
Antisense	   5'-GCCAGGCAGTAGAAGACGTAA-3’	  
Table	  S10.	  Sequence	  of	  primers	  used	  for	  nested-­‐PCR	  amplification	  
Gene	   Primers	   Localisation	  to	  TSS	  
Size	  
(bp)	  
Number	  
of	  CpG	  
3-­‐OST3A	  
5’	  Region	  
Out	  sense	   5’-TAGTGTTAAGAGGGGAGTAG-3' -­‐454	  to	  
+281	  
735	   46	  
Out	  
antisense	   5’-CTTTCTCTAATCCCCTTACC-3’ 
In	  sense	   5’-ATTAAGTTAGTGGCGTTTGGG-3’ -­‐360	  to	  
+120	  
480	  
In	  
antisense	   5’-CTACTCTTAAACCCCACCTAT-3’ 
3-­‐OST3A	  
3’	  Region	  
Out	  sense	   5’-ATAGGTGGGGTTTAAGAGTAG-3’ +100	  to	  
+768	  
668	   54	  
Out	  
antisense	   5’-CCGACCATACTAAACCTAAAC-3’ 
In	  sense	   5’-GGAAAGGGGATTAGAGAAAG-3’ +262	  to	  
+746	  
484	  
In	  
antisense	   5’-CCGACAAATACCAAAACATCC-3’ 
	  
First	  round	  of	  PCR	  was	  performed	  with	  primers	  “Out	  sense”	  and	  “Out	  antisense”	  and	  second	  round	  
of	  PCR	  was	  performed	  with	  primers	  “In	  sense”	  and	  “In	  antisense”.	  TSS,	  transcription	  start	  site.	  
Table	  S11.	  Antibodies	  used	  for	  ChIP	  analyses.	  	  
Antibody	   Catalog	  information	   Source	  
Quantity	  
/ChIP	  
DNMT1	  (mAb)	  	   Active	  Motif	  39204	   mouse	   5-­‐10	  µg	  
DNMT3A	  (mAb)	  	   Active	  Motif	  39206	   mouse	   5-­‐10	  µg	  
DNMT3B	  (mAb)	  	   Active	  Motif	  39207	   mouse	   5-­‐10	  µg	  
Histone	  H3K4me3	  (pAb)	  	   Active	  Motif	  39915	   rabbit	   5-­‐10	  µg	  
Histone	  H3K9me3	  (pAb)	  	   Active	  Motif	  39161	   rabbit	   5-­‐10	  µg	  
Histone	  H3K27me3	  (pAb)	  	   Active	  Motif	  39155	   rabbit	   5-­‐10	  µg	  
EZH2	  (mAb)	   Active	  Motif	  39875	   mouse	   1-­‐3	  µg	  
SUZ12	  (pAb)	   Diagenode	  C15310029	   rabbit	   5	  µg	  
HDAC1	  (pAb)	  	   Invitrogen	  Life	  technologies	  49-­‐1025	   rabbit	   5-­‐10	  µg	  
MeCP2	  (pAb)	  	   Diagenode	  pAb-­‐052-­‐050	   rabbit	   5-­‐10	  µg	  
Sin3A	  (pAb)	   Active	  Motif	  39865	   rabbit	   5-­‐10	  µg	  
Monoclonal	  (m),	  polyclonal	  (p)	  antibodies	  (Ab).	  	  
Table	  S12.	  Sequence,	  size,	  location	  relative	  to	  TSS	  and	  Tm	  of	  PCR	  primers	  for	  ChIP	  analyses	  
Primers	   Size	  	  (bp)	   Location	  to	  TSS	   Tm	  (°C)	  
Set	  1	   Sense	   5’-GCGTCTTGGGTGGAAGTCAG-3’  219	   -­‐347/-­‐129	   65	  
	  
65	  
	  
65	  
Antisense	   5’-TGGGATGGAGAAAAGGTGGC-3’  
Set	  2	  	   Sense	   5’-CCTTGGCTGAGAGAACCTGAAC-3’  178	   +216/+393	  
Antisense	   5’-TCAGCGATCCTGCATCACTGGC-3’  
Set	  3	  	   Sense	   5’-GCCAAGGCTGCCCCAAGCTCA-3’  138	   +468/+605	  
Antisense	   5’-CAGGATCCCTGCCTCCAGTC-3’  
	  
